CA2938712C - Soluble and immunoreactive variants of htlv capsid antigen p24 - Google Patents

Soluble and immunoreactive variants of htlv capsid antigen p24 Download PDF

Info

Publication number
CA2938712C
CA2938712C CA2938712A CA2938712A CA2938712C CA 2938712 C CA2938712 C CA 2938712C CA 2938712 A CA2938712 A CA 2938712A CA 2938712 A CA2938712 A CA 2938712A CA 2938712 C CA2938712 C CA 2938712C
Authority
CA
Canada
Prior art keywords
htlv
antigens
soluble
antigen
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2938712A
Other languages
English (en)
French (fr)
Other versions
CA2938712A1 (en
Inventor
Elke Faatz
Peter Muench
Christian Scholz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2938712A1 publication Critical patent/CA2938712A1/en
Application granted granted Critical
Publication of CA2938712C publication Critical patent/CA2938712C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14051—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2938712A 2014-02-28 2015-02-26 Soluble and immunoreactive variants of htlv capsid antigen p24 Active CA2938712C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14157165.3 2014-02-28
EP14157165.3A EP2913338A1 (en) 2014-02-28 2014-02-28 Soluable and immunoreactive variants of HTLV capsid antigen p24
PCT/EP2015/053966 WO2015128394A2 (en) 2014-02-28 2015-02-26 Soluble and immunoreactive variants of htlv capsid antigen p24

Publications (2)

Publication Number Publication Date
CA2938712A1 CA2938712A1 (en) 2015-09-03
CA2938712C true CA2938712C (en) 2018-10-23

Family

ID=50184798

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2938712A Active CA2938712C (en) 2014-02-28 2015-02-26 Soluble and immunoreactive variants of htlv capsid antigen p24

Country Status (7)

Country Link
US (2) US10466242B2 (enExample)
EP (2) EP2913338A1 (enExample)
JP (1) JP6491228B2 (enExample)
CN (1) CN106029687B (enExample)
CA (1) CA2938712C (enExample)
ES (1) ES2662611T3 (enExample)
WO (1) WO2015128394A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017153336A1 (en) * 2016-03-07 2017-09-14 F. Hoffmann-La Roche Ag Detection of anti-p53 antibodies
PL3759233T4 (pl) * 2018-02-26 2022-10-10 Technische Universiteit Eindhoven Bioczujnik bioluminescencyjny do wykrywania i oznaczania ilościowego biocząsteczek
WO2021214248A1 (en) * 2020-04-23 2021-10-28 F. Hoffmann-La Roche Ag Corona nucleocapsid antigen for use in antibody-immunoassays
WO2026027625A1 (en) * 2024-07-31 2026-02-05 Roche Diagnostics Gmbh Hepatitis delta virus polypeptides and detection

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2564268B2 (ja) * 1985-08-28 1996-12-18 協和醗酵工業株式会社 融合抗原ポリペプチド
NZ238855A (en) * 1990-07-18 1994-03-25 Iaf Biochem Int Peptides, mixtures thereof and compositions useful for detecting htlv-i and htlv-ii infections
DE69330164T2 (de) * 1992-02-24 2002-01-17 Genelabs Technologies, Inc. Htlv-i/htlv-ii assay und verfahren
WO1996039630A1 (en) * 1995-06-05 1996-12-12 Abbott Laboratories Detection of htlv antibodies utilizing recombinant proteins
WO1998013496A1 (en) 1996-09-26 1998-04-02 Medical Research Council Chaperone fragments
JP2000078973A (ja) * 1998-09-03 2000-03-21 Tonen Corp Ｈｔｌｖ−ｉ組換え抗原
JP2003506411A (ja) * 1999-08-09 2003-02-18 トリペップ アクチ ボラゲット タンパク質重合阻害剤および使用方法
US6258932B1 (en) * 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
KR100702373B1 (ko) 2001-06-22 2007-04-02 에프. 호프만-라 로슈 아게 레트로바이러스 표면 당단백질을 함유하는 가용성 복합체
ATE529436T1 (de) * 2007-04-20 2011-11-15 Hoffmann La Roche Erkennung von primären infektionen mit krankheitserregern
EP2127678A1 (en) * 2008-05-26 2009-12-02 Roche Diagnostics GmbH SlpA as a tool for recombinant protein and enzyme technology

Also Published As

Publication number Publication date
EP2913338A1 (en) 2015-09-02
ES2662611T3 (es) 2018-04-09
JP6491228B2 (ja) 2019-03-27
US20200033342A1 (en) 2020-01-30
US10466242B2 (en) 2019-11-05
CN106029687A (zh) 2016-10-12
CN106029687B (zh) 2020-07-31
WO2015128394A2 (en) 2015-09-03
JP2017512200A (ja) 2017-05-18
EP3110831B1 (en) 2018-01-10
US20170184591A1 (en) 2017-06-29
EP3110831A2 (en) 2017-01-04
WO2015128394A3 (en) 2015-11-05
CA2938712A1 (en) 2015-09-03
US11567079B2 (en) 2023-01-31

Similar Documents

Publication Publication Date Title
MX2022001954A (es) Diagnosticos representativos.
EA201590184A1 (ru) Вакцина на основе микобактериальных антигенов
MX353464B (es) Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles.
MX2020009021A (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco.
WO2013070776A8 (en) Neutralizing gp41 antibodies and their use
AR098126A1 (es) Anticuerpos anti-ly6e (locus e del complejo del antígeno 6 linfocítico), inmunoconjugados y métodos para usarlos
CN103819559B (zh) 一种抗间皮素纳米抗体及其编码基因和该纳米抗体的用途
MX363403B (es) Inmumoensayo con interferencia suprimida para la deteccion de anticuerpos anti-farmacos en muestras de suero.
MX358772B (es) Metodo para detectar cancer.
WO2015112558A3 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
CA2938712C (en) Soluble and immunoreactive variants of htlv capsid antigen p24
CL2012001980A1 (es) Uso de un anticuerpo monoclonal anti-cd44 o fragmento de unión del mismo, en el tratamiento del carcinoma escamocelular de cabeza y cuello (hnscc) en un mamífero, donde el hnscc se distingue según la expresión de cd44.
EP2577307A4 (en) DIAGNOSTIC TEST
WO2011055968A3 (en) Kit for detecting bacterial infection comprising novel monoclonal antibodies
WO2017218677A3 (en) Identification and medical applications of anti-citrullinated-protein antibodies in rheumatoid arthritis
TW201613981A (en) Compositions and methods for the diagnosis of rheumatoid arthritis
JP2015529211A5 (enExample)
EP4196770A4 (en) TR-FRET-BASED ASSAY FOR THE DETECTION OF ANTIBODIES IN SEROLOGICAL SAMPLES
PH12016501579B1 (en) Novel anti-presepsin antibody
EP4257976A3 (en) Mycobacterium tuberculosis proteins in diagnostic assays and devices for tuberculosis detection and diagnosis
WO2016075546A3 (en) Antibodies that neutralize ebola virus and uses thereof
WO2015134928A3 (en) Point of care assays to detect the status of tuberculosis infection
WO2023109979A3 (zh) 一种展示新冠s蛋白的融合蛋白和重组病毒粒子及其应用
MX374731B (es) Método para la detección de un anticuerpo igm específico para un flavivirus en una muestra.
JP2017512200A5 (enExample)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160803

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250123

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250123